AZD8055, mTOR Inhibitor


Catalog No. size PriceQuantity
M60091-5S 5 mg solid $69
M60091-50S 50mg solid $370

Description

Product Information
Chemical Name: (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methano
Molecular Weight: 465.54
Formula: C25H31N5O4
Purity: ≥ 98%
CAS#: 1009298-09-2
Solubility: DMSO up to 100 mM
Storage: Powder: 4oC 1 year DMSO: 4oC 3 month -20oC 1 year

 


Biological Activity:

AZD8055 is a highly potent, selective and ATP-competitive mTOR inhibitor (IC50 = 0.8 nM). It has >1,000-fold selectivity against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). It has no significant activity against a panel of 260 kinases at concentrations up to 10 µM. AZD8055 inhibits the phosphorylation of mTORC1 downstream targets (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 downstream proteins (e.g., Akt). The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation of U87MG, A549 and H838 cells with IC50 of 53, 50, and 20 nM, respectively. It also induces autophagy and increases LC3-II levels in H838 and A549 cells.  AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors, and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. It also shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10-20 mg/kg. AZD8055 was previously evaluated in a phase I clinical study in patients with advanced tumors. 


How to Use:

In vitro: AZD8055 was used at 2.5 µM concentration in vitro and cellular assays.

In vivo: AZD8055 was orally dosed to mice at 2.5-20 mg/kg once or twice per day to inhibit tumor growth.


Reference:

  1. Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.  (2010) Cancer Res. 70(1):288-98.
  2. García-Martínez JM, et al. Effect of PI3K- and  mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. (2011) Br J Cancer. 104(7):1116-25.
  3. Jiang Q, et al. mTOR kinase inhibitor AZD8055  enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.(2011) Cancer Res. 71(12):4074-84.
  4. Huang S, et al. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. (2011) J Biol Chem.  286(46):40002-12.
  5. Willems L, et al. The dual mTORC1 and mTORC2  inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. (2012) Leukemia. 26(6):1195-202.
  6. Holt SV, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). (2012) Cancer Res. 72(7):1804-13.
  7. Naing A, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours  and lymphoma. (2012) Br J Cancer. 107(7):1093-9.
  8. Pike KG, et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014. (2013) Bioorg Med Chem Lett. In press.

Products are for research use only. Not for human use.

 

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed